Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes

被引:17
|
作者
El-Ashmawy, Hazem M. [1 ]
Ahmed, Azza M. [2 ]
机构
[1] Zagazig Univ, Fac Med, Dept Internal Med, Zagazig, Egypt
[2] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt
关键词
fetuin-B; nonalcoholic fatty liver disease; type 2 diabetes mellitus; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; A LEVELS; RISK; ATHEROSCLEROSIS; STEATOHEPATITIS; INFLAMMATION; ASSOCIATION; GLUCOSE;
D O I
10.1097/MEG.0000000000001354
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Previous studies have assessed serum fetuin-B and its relation to nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) and as a link between them through inducing insulin resistance (IR). Therefore, we examined the potential of serum fetuin-B to be an independent marker for NAFLD in patients with T2DM. Patients and methods The study group consisted of 270 patients with T2DM. Clinical and laboratory features were evaluated. The NAFLD severity was graded by ultrasound into three subgroups: grade 0 (no fatty liver), grade 1 (mild fatty liver), and grade 2-3 (medium to severe fatty liver). Fetuin-B, retinol-binding protein-4, and adiponectin were measured. Results Patients with grade 2-3 NAFLD had high fetuin-B levels in comparison with non-NAFLD group. Age and sex adjusted fetuin-B demonstrated positive correlations with triglycerides, gamma-glutamyl transferase, fasting plasma glucose, 2-h postprandial plasma glucose, homeostasis model assessment of IR, fasting insulin, glycated hemoglobin, high-sensitivity C-reactive protein, and estimated glomerular filtration rate, but it had a negative correlation with serum creatinine. Adiponectin level was decreased with increasing NAFLD severity, but no difference was found in retinol-binding protein-4. The estimated odds ratio (OR) for the occurrence of grade 2-3 NAFLD was increased significantly with increasing levels of fetuin-B (OR: 3.92; 95% confidence interval: 2.14-8.32 vs. OR: 8.91; 95% confidence interval: 4.22-18.41). The OR of fetuin-B in the uppermost tertile group was still significant after controlling for homeostasis model assessment of IR, glycated hemoglobin, waist circumference, BMI, hepatic enzymes, high-density lipoprotein cholesterol, triglycerides, and high-sensitivity C-reactive protein. Conclusions Our study demonstrated that serum fetuin-B had an independent association with NAFLD in patients with T2DM.
引用
收藏
页码:859 / 864
页数:6
相关论文
共 50 条
  • [31] The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Golabi, Pegah
    Price, Jillian Kallman
    Owrangi, Soroor
    Gundu-Rao, Nagashree
    Satchi, Romona
    Paik, James M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (10) : 1999 - 2010
  • [32] Serum Tsukushi Is Associated with HDL Dysfunction in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Tan, Kathryn C. B.
    Lam, Sum
    Lui, David T.
    Fong, Ho Yi
    Wong, Ying
    Shiu, Sammy
    Lee, Chi Ho
    DIABETES, 2024, 73
  • [33] IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Bian, Hua
    Zhu, Xiaopeng
    Xia, Mingfeng
    Yan, Hongmei
    Chang, Xinxia
    Hu, Xiqi
    Pan, Baishen
    Guo, Wei
    Li, Xiaoying
    Gao, Xin
    ENDOCRINE PRACTICE, 2020, 26 (04) : 444 - 453
  • [34] Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease
    Wang, Chao-Hung
    Leung, Ching-Hsiang
    Liu, Sung-Chen
    Chung, Cheng-Ho
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2006, 105 (09) : 743 - 752
  • [35] Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)
    Saenz, Enrique Valdez
    Leiva, Eddison Godinez
    Lomonaco, Romina
    Marangi, Stephen A.
    Kalavalapalli, Srilaxmi
    Gonzalez, Maria A.
    Chi, Xiaofei
    Rocha, Andrea Ortiz
    Mohseni, Yasmine
    Barb, Diana
    Gurka, Matthew J.
    Sharma, Anu
    Cusi, Kenneth
    DIABETES, 2023, 72
  • [36] Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
    Ciardullo, Stefano
    Vergani, Michela
    Perseghin, Gianluca
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [37] Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
    Paola Portillo-Sanchez
    Kenneth Cusi
    Clinical Diabetes and Endocrinology, 2 (1):
  • [38] Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
    Bril, Fernando
    Cusi, Kenneth
    DIABETES CARE, 2017, 40 (03) : 419 - 430
  • [39] Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes
    Targher, Giovanni
    Valbusa, Filippo
    Bonapace, Stafano
    Bertolini, Lorenzo
    Zenari, Luciano
    Pichiri, Isabella
    Mantovani, Alessandro
    Zoppini, Giacomo
    Bonora, Enzo
    Barbieri, Enrico
    Byrne, Christopher D.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2014, 24 (06) : 663 - 669
  • [40] Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes in a Spanish Population
    Sanchez Bao, Ana M., Jr.
    Bellido, Virginia
    Tejera, Cristina
    Bellido, Diego, Sr.
    DIABETES, 2020, 69